We are live on ! Find out more
OM

Opaleye Management Portfolio holdings

AUM $1.1B
1-Year Est. Return 197.64%
This Fund
S&P 500
This Quarter Est. Return
+75.06%
1 Year Est. Return
+197.64%
3 Year Est. Return
+748.31%
5 Year Est. Return
+1,163.14%
10 Year Est. Return
+87,953.74%
AUM
$495M
AUM Growth
+$118M
Cap. Flow
-$4.08M
Cap. Flow %
-0.82%
Top 10 Hldgs %
52.26%
Holding
60
New
16
Increased
13
Reduced
8
Closed
12

Top Buys

Rank Stock Value
1
FBIO icon
Fortress Biotech
FBIO
+$9.48M
2
KNSA icon
Kiniksa Pharmaceuticals
KNSA
+$7.2M
3
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$6.09M
4
OCUL icon
Ocular Therapeutix
OCUL
+$5.71M
5
CYTK icon
Cytokinetics
CYTK
+$5.68M

Top Sells

Rank Stock Value
1
FTSV
Forty Seven, Inc. Common Stock
FTSV
+$36.8M
2
APTO
Aptose Biosciences, Inc.
APTO
+$6.39M
3
KDMN
Kadmon Holdings, Inc.
KDMN
+$4.83M
4
KALA icon
KALA BIO
KALA
+$4.76M
5
ZYME icon
Zymeworks
ZYME
+$4.72M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
OCUL icon
51
CALL
Ocular Therapeutix
OCUL
$2.38B
– –
-1,000
Closed -$53K
RNAC icon
52
Cartesian Therapeutics
RNAC
$302M
– –
-13,000
Closed -$940K
VSTM icon
53
Verastem
VSTM
$668M
– –
-121,992
Closed -$3.87M
ZYME icon
54
Zymeworks
ZYME
$2.07B
– –
-133,000
Closed -$4.72M
PRVB
55
DELISTED
Provention Bio, Inc. Common Stock
PRVB
– –
-166,000
Closed -$1.53M
RDUS
56
DELISTED
Radius Health, Inc.
RDUS
– –
-167,000
Closed -$2.17M
FLXN
57
DELISTED
Flexion Therapeutics, Inc.
FLXN
– –
-281,600
Closed -$2.22M
KDMN
58
DELISTED
Kadmon Holdings, Inc.
KDMN
– –
-1,152,250
Closed -$4.83M
FTSV
59
DELISTED
Forty Seven, Inc. Common Stock
FTSV
– –
-385,500
Closed -$36.8M
1 2
3

Similar funds

CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
PFM
Premier Fund Managers Guildford, United Kingdom $1.1B AUM 14.42% 1-Year Est. Return
HBCM
Heron Bay Capital Management Bloomfield Hills, Michigan $1.1B AUM 11.31% 1-Year Est. Return
HAS
HBW Advisory Services Simi Valley, California $1.11B AUM 25.66% 1-Year Est. Return
AI
Aperture Investors New York $1.11B AUM 81.44% 1-Year Est. Return
TPA
Trivium Point Advisory Westport, Connecticut $1.1B AUM 28.81% 1-Year Est. Return
ZDA
Zweig-DiMenna Associates New York $1.1B AUM 171.86% 1-Year Est. Return
NW
Naviter Wealth Little Rock, Arkansas $1.1B AUM 33.28% 1-Year Est. Return

Opaleye Management's Q2 2020 Portfolio in Review

As of Q2 2020, Opaleye Management held 60 positions worth $495M, up 31% from $377M the previous quarter. Its ten largest holdings account for 52% of the portfolio.

Opaleye Management's Q2 2020 filing shows 16 new, 13 increased, 8 reduced and 12 closed positions. Its largest new stake was Fortress Biotech: 255,333 shares worth $10.3M. The largest sale was Forty Seven, Inc. Common Stock, an estimated $36.8M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 98% a quarter earlier.

  • Opaleye Management's largest Q2 2020 buy was Fortress Biotech: 255,333 shares worth $10.3M.
  • Opaleye Management added most to Ocular Therapeutix in Q2 2020, an estimated $5.71M increase.
  • Opaleye Management's biggest Q2 2020 reduction was Aptose Biosciences, Inc., cutting an estimated $6.39M.
  • Opaleye Management fully exited Forty Seven, Inc. Common Stock in Q2 2020, selling an estimated $36.8M.
  • Opaleye Management's ten largest holdings make up 52% of its $495M portfolio in Q2 2020.
  • Opaleye Management opened 16 new positions and closed 12 in Q2 2020.
  • Opaleye Management's portfolio value rose 31% quarter-over-quarter to $495M.

Based on Opaleye Management's 13F filing for Q2 2020, filed 14 Aug 2020.